Loading...
•
Sep 30
Health Catalyst Q3 2025 Earnings Report
Health Catalyst reported a Q3 net loss of $22.2 million while achieving strong adjusted EBITDA growth and maintaining stable revenue.
Key Takeaways
Health Catalyst delivered Q3 2025 revenue in line with the prior year at $76.3 million, improved adjusted EBITDA by 64%, and enhanced gross margins, despite a GAAP net loss of $22.2 million due to restructuring and lease-related charges.
Revenue for Q3 2025 held steady at $76.3 million compared to Q3 2024.
Adjusted EBITDA rose 64% year-over-year to $12 million.
Adjusted Gross Profit reached $40.1 million with a margin of 53%.
Company ended the quarter with $40.3 million in cash and equivalents.
Health Catalyst
Health Catalyst
Health Catalyst Revenue by Segment
Revenue by Segment
Technology Revenue
CapyFin.comProfessional Services Revenue
CapyFin.com Forward Guidance
For Q4 2025, Health Catalyst expects slightly lower revenue but improved profitability, driven by continued cost control and targeted investments.
Positive Outlook
- Q4 revenue expected at $73.5 million, supporting stable top-line performance.
- Adjusted EBITDA guidance for Q4 is $13.4 million, up from Q3.
- Full-year revenue guidance reaffirmed at $310 million.
- Continued investment in high-ROI solutions expected to yield sustained results.
- Focus on strategic cost management improving operating leverage.
Challenges Ahead
- Q3 net loss increased YoY to $22.2 million due to restructuring and lease impairments.
- Cash and cash equivalents dropped significantly from $249.6 million at year-end to $40.3 million.
- Professional services revenue declined YoY by 12.3%.
- GAAP operating loss persisted despite revenue stability.
- One-time charges such as $6.9 million lease impairment impacted bottom-line results.
Revenue & Expenses
Visualization of income flow from segment revenue to net income